Intelligent Bio Solutions Inc. (INBS)
- Sector
- Healthcare
- Industry
- Medical Devices
- Last price
- $1.48
- As of
Kresmion compiles this page from INBS's SEC filings, its 13F institutional holders and the market events Kresmion detects, each linked to its source.
INTELLIGENT BIO SOLUTIONS INC. (INBS): no institutional manager tracked by Kresmion reported a non-option position in the latest Form 13F reporting quarter, and the most recent SEC filing on record for the company is a Form 8-K filed 2026-10-13.
See the full INBS dossier
Price with insider and filing markers, who is positioning, fundamentals and peers for INBS on one page. Preview it with sample data, then open it live with a free account.
Preview the INBS dossierActive signals for INBS
- mediumEARNINGS_BEAT
Q4-2026: Beat consensus by 44.2%, EPS $-0.90 vs $-1.6116 estimate
- mediumEARNINGS_BEAT
Q2-2024: Beat consensus by 37.4% - EPS $-20.7 vs $-33.048 estimate
- mediumEARNINGS_MISS
Q3-2024: Missed consensus by 61.1% - EPS $-14.3 vs $-8.874 estimate
- mediumEARNINGS_MISS
Q4-2024: Missed consensus by 157.6% - EPS $-13.4 vs $-5.202 estimate
- mediumEARNINGS_MISS
Q1-2025: Missed consensus by 29.5% - EPS $-7 vs $-5.406 estimate
FREE, NO ACCOUNT
Every signal on INBS, as it fires
You are seeing 5 of 9 signals recorded on INBS since 2026-05-27.
The five above landed across 2 days. The other 4 were recorded on 1 other days.
No fixed schedule: it goes out when the data has something in it. Unsubscribe anytime. We never sell your data.
No non-option holdings from tracked managers in this reporting quarter. Historical quarters remain available above.
Recent SEC filings, INBS
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 10-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
INBS mentioned in Kresmion daily briefs
INBS against its peers
INBS's operating margin of -299.1% ranks in the 42nd percentile of 12 Medical Devices sub-industry peers, fiscal periods ending between 2025-12-31 and 2026-06-30.
| Metric | INBS | Peer median | Percentile | n |
|---|---|---|---|---|
| Revenue FY | 4.2M USD | 2.4M USD | 77 | 14 |
| Gross margin | 48.6% | 50.1% | 50 | 10 |
| Operating margin | -299.1% | -141.2% | 42 | 12 |
| Net margin | -294.9% | -250.6% | 50 | 12 |
| Return on equity | -225.6% | -166.4% | 32 | 13 |
| 1 year | -86.2% | -92.6% | 61 | 13 |
Peers (18): VVOS, USAQ, NVNO, STME, AIDX, AMIX, NXL, VNRX, ADGM, ICCM, TANAF, IVF, BJDX, CODX, ADMT, BMRA, AEMD, TNON. Left out: SONX (period gap), TRIB (period gap), KLYG (no annual filing), CYDX (no annual filing), WOK (period gap), PMEDF (period gap), NMTC (no annual filing). Fiscal periods ending between 2025-12-31 and 2026-06-30. Every figure is one full fiscal year read from one annual filing (INBS: 10-K), reported in USD. Nothing is trailing twelve months and nothing is converted between currencies. Source: SEC EDGAR XBRL company facts (public domain); prices from Kresmion's daily equity market-data snapshot. Open the full comparison.
Related tickers
Follow INBS on a live board
Kresmion is a cross-asset market-intelligence terminal. Open a board scoped to INBS for its filings, 13F changes, insider trades, options positioning, and confluence read in one view, each with its source.